AML drug resistance: C-Myc comes into play

Blood

Volumn 123, Issue 23, 2014, Pages 3528-3530

  Fauriat, Cyril ^a   Olive, Daniel ^a  

^a Institut National de la Santé et de la Recherche Médicale   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ATM PROTEIN; CYTARABINE; HISTONE DEACETYLASE INHIBITOR; MYC PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; DNA DAMAGE; HLA SYSTEM; HUMAN; LEUKEMIA CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CYTOTOXICITY, IMMUNOLOGIC; GPI-LINKED PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84902140778     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-566711     Document Type: Review

References (10)

1. Nanbakhsh A, Pochon C, Mallavialle A, Amsellem S, Bourhis JH, Chouaib S. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood. 2014; 123(23):3585-3595.
2. Diermayr S, Himmelreich H, Durovic B, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 2008; 111(3):1428-1436. (Pubitemid 351213430)
3. Kato N, Tanaka J, Sugita J, et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia. 2007;21(10): 2103-2108. (Pubitemid 47423800)
4. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113(15): 3503-3511.
5. Cerboni C, Fionda C, Soriani A, et al. The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol. 2014;4:508.
6. Chretien AS, Le Roy A, Vey N, et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol. 2014;5:122.
7. Sanchez-Correa B, Morgado S, Gayoso I, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother. 2011;60(8): 1195-1205.
8. Schmiedel BJ, Arélin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer. 2011; 128(12):2911-2922.
9. Elias S, Yamin R, Golomb L, et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood. 2014; 123(10):1535-1543.
10. Fiegler N, Textor S, Arnold A, et al. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 2013;122(5):684-693.